New combo therapy boosts immune recovery in late-diagnosed HIV patients
NCT ID NCT00302822
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether adding an extra HIV drug (enfuvirtide) to standard treatment for 6 months helps people with very low CD4 counts recover their immune system faster. It included 195 adults newly diagnosed with HIV who had a high risk of getting AIDS. The goal was to see if more patients could reach a safe CD4 level after 24 weeks of treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AIDS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Service des Maladies Infectieuses A Hôpital Bichat-Claude Bernard
Paris, 75018, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a plasma beam stop anal lesions from becoming cancer?
- Can resilience defeat HIV stigma? a new study investigates
- Peer support may curb HIV stigma and stress in vietnamese gay men
- A pharmacist's touch: could structured medication reviews boost HIV treatment success?
- A new Fast-Track HIV care model aims to Re-Engage those lost to care
- Can a smartphone app curb HIV risk in south Korea's young gay men?